1
|
Green MV, Seidel J, Williams MR, Wong KJ, Ton A, Basuli F, Choyke PL, Jagoda EM. Comparison of planar, PET and well-counter measurements of total tumor radioactivity in a mouse xenograft model. Nucl Med Biol 2017; 53:29-36. [PMID: 28797928 DOI: 10.1016/j.nucmedbio.2017.06.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Revised: 06/22/2017] [Accepted: 06/26/2017] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Quantitative small animal radionuclide imaging studies are often carried out with the intention of estimating the total radioactivity content of various tissues such as the radioactivity content of mouse xenograft tumors exposed to putative diagnostic or therapeutic agents. We show that for at least one specific application, positron projection imaging (PPI) and PET yield comparable estimates of absolute total tumor activity and that both of these estimates are highly correlated with direct well-counting of these same tumors. These findings further suggest that in this particular application, PPI is a far more efficient data acquisition and processing methodology than PET. METHODS Forty-one athymic mice were implanted with PC3 human prostate cancer cells transfected with prostate-specific membrane antigen (PSMA (+)) and one additional animal (for a total of 42) with a control blank vector (PSMA (-)). All animals were injected with [18F] DCFPyl, a ligand for PSMA, and imaged for total tumor radioactivity with PET and PPI. The tumors were then removed, assayed by well counting for total radioactivity and the values between these methods intercompared. RESULTS PET, PPI and well-counter estimates of total tumor radioactivity were highly correlated (R2>0.98) with regression line slopes near unity (0.95<slope≤1.02) and intercepts near zero (-0.001MBq≤intercept ≤0.004MBq). CONCLUSION Total mouse xenograft tumor radioactivity can be measured with PET or PPI with an accuracy comparable to well counting if certain experimental and pharmacokinetic conditions are met. In this particular application, PPI is significantly more efficient than PET in making these measurements.
Collapse
Affiliation(s)
- Michael V Green
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Contractor to Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD.
| | - Jurgen Seidel
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Contractor to Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD
| | - Mark R Williams
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Contractor to Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD
| | - Karen J Wong
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Anita Ton
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Falguni Basuli
- Imaging Probe Development Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Peter L Choyke
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Elaine M Jagoda
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
| |
Collapse
|
4
|
Jagoda EM, Bhattacharyya S, Kalen J, Riffle L, Leeder A, Histed S, Williams M, Wong KJ, Xu B, Szajek LP, Elbuluk O, Cecchi F, Raffensperger K, Golla M, Bottaro DP, Choyke P. Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [
99m
Tc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide. Mol Imaging 2015. [DOI: 10.2310/7290.2015.00023] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Elaine M. Jagoda
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Sibaprasad Bhattacharyya
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Joseph Kalen
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Lisa Riffle
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Avrum Leeder
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Stephanie Histed
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Mark Williams
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Karen J. Wong
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Biying Xu
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Lawrence P. Szajek
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Osama Elbuluk
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Fabiola Cecchi
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Kristen Raffensperger
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Meghana Golla
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Donald P. Bottaro
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| | - Peter Choyke
- From the Molecular Imaging Program, National Cancer Institute (NCI), Bethesda, MD; ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Small Animal Imaging Program, NCI, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick, MD; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Rockville, MD; PET Department, Clinical Center, NIH,
| |
Collapse
|